Rheumatoid arthritis patients treated with the JAK1 selective inhibitor upadacitinib experience greater improvement in the signs and symptoms of disease than those given placebo or adalimumab, indicate findings from the SELECT COMPARE trial.
William Tillett, Deepak Jadon, and Jobie Evans debate the clinical reasons relating to the efficacy, safety, and practicality of using etanercept or methotrexate as first-line therapy for psoriatic arthritis.
A Japanese genome-wide association study has identified novel genetic loci associated with the susceptibility of gout in individuals with asymptomatic hyperuricemia.
Estimated remission and retention rates do not differ significantly among patients with rheumatoid arthritis treated with either certolizumab pegol, abatacept, or biosimilar infliximab, show the results of a surrogate randomized controlled trial.
Real-world study results suggest that mild tapering of tumor necrosis factor inhibitors does not influence the probability of achieving inactive disease among patients with axial spondyloarthritis.
Vitamin D intake is inversely associated with cartilage degeneration among patients with osteoarthritis, and supplementation may have a protective effect, suggests an analysis of data from the Osteoarthritis Initiative.
Rheumatoid arthritis patients treated with the JAK1 selective inhibitor upadacitinib experience greater improvement in the signs and symptoms of disease than those given placebo or adalimumab, indicate findings from the SELECT COMPARE trial.
medwireNews takes a look at the efficacy and safety profiles of JAK inhibitors for the treatment of rheumatoid arthritis, and addresses some common questions about their use.
Rheumatoid arthritis patients treated with the JAK1 selective inhibitor upadacitinib experience greater improvement in the signs and symptoms of disease than those given placebo or adalimumab, indicate findings from the SELECT COMPARE trial.
